Your browser doesn't support javascript.
loading
Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.
Gebrie, Habtamu; Yimer, Mulat; Ayehu, Animen; Mohammed, Hussien; Hailgiorgis, Henok; Wuletaw, Yonas; Hailu, Mesay; Tolera, Getachew; Tasew, Geremew; Kassa, Mogess; Gidey, Bokretsion.
Afiliação
  • Gebrie H; Department of Medical Laboratory Science College of Medicine and Health Science, Dilla University, Dilla, Ethiopia. habtamugebrie2012@gmail.com.
  • Yimer M; Department of Medical Laboratory Science College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia.
  • Ayehu A; Department of Medical Laboratory Science College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia.
  • Mohammed H; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Hailgiorgis H; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Wuletaw Y; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Hailu M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Tolera G; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Tasew G; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Kassa M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
  • Gidey B; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Malar J ; 23(1): 202, 2024 Jul 06.
Article em En | MEDLINE | ID: mdl-38971786
ABSTRACT

BACKGROUND:

Plasmodium vivax malaria is still an important public health problem in Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that can be a risk of recurrent vivax malaria unless treated by radical cure with primaquine. Drug resistance to chloroquine is threatening malaria control and elimination efforts. This study assessed the therapeutic efficacy and safety of chloroquine plus 14 days of primaquine on P. vivax infection based on parasitological, clinical, and haematological parameters.

METHODS:

A single-arm in vivo prospective therapeutic efficacy study was conducted to assess the clinical and parasitological response to the first-line treatment of P. vivax in Ethiopia, chloroquine plus 14 days low dose of (0.25 mg/kg/day) primaquine between December 2022 and March 2023 at Hamusit Health Centre using the standard World Health Organization (WHO) protocol. A total of 100 study participants with P. vivax mono-infection who were over 6 months old were enrolled and monitored for adequate clinical and parasitological responses for 42 days. The WHO double-entry Excel sheet and SPSS v.25 software were used for Kaplan-Meier survival analysis, and a paired t-test was used for analysis of haemoglobin improvements between follow up days.

RESULTS:

A total of 100 patients were enrolled among those, 96% cases were rural residents, 93% had previous malaria exposure, and predominant age group was 5-15 years (61%). 92.6% (95% CI 85.1-96.4%) of enrolled patients were adequate clinical and parasitological response, and 7.4% (95% CI 3.6-14.9%) recurrences were observed among treated patients. The fever and parasite clearance rate on day 3 were 98% and 94%, respectively. The baseline haemoglobin levels improved significantly compared to those days 14 and 42 (p < 0.001). No serious adverse event was observed during the study period.

CONCLUSIONS:

In this study, co-administration of chloroquine with primaquine was efficacious and well-tolerated with fast resolution of fever and high parasites clearance rate. However, the 7.4% failure is reported is alarming that warrant further monitoring of the therapeutic efficacy study of P. vivax.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium vivax / Primaquina / Cloroquina / Malária Vivax / Quimioterapia Combinada / Antimaláricos Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Africa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plasmodium vivax / Primaquina / Cloroquina / Malária Vivax / Quimioterapia Combinada / Antimaláricos Limite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Africa Idioma: En Ano de publicação: 2024 Tipo de documento: Article